Systemic Anti-Cancer Therapy Regimen Library
LYM NHL B-cell - R-CHOP21 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]
Treatment Overview
Number of cycles: 3 to 8.
This regimen contains a medicine where one or more biosimilars may exist. Any biosimilars used have been reviewed by the regulator (Medsafe) and relevant specialists were consulted nationally. Where regulators, in consultation with relevant specialists, have agreed that there are no clinically significant differences in either safety or effectiveness between a biosimilar and originator product, these drugs may be used interchangeably.
Cycles 1 to 8 - 21 days
RITUximab, first dose:
- Consider withholding routine anti-hypertensives for 12 hours prior to first RITUximab dose.
- For patients at high risk of infusion-related reaction, consider additional pre-medications such as an extra antihistamine dose the day before, an H2 receptor antagonist and montelukast.
Cycle details
Cycles 1 to 8 - 21 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| prEDNISone | 100 mg flat dosing Once daily | oral administration | 1 to 5 | |
| paracetamol * | 1000 mg flat dosing | oral administration | 1 | |
| loratadine * | 10 mg | oral administration | 1 | |
| RITUximab | 375 mg/m² | intravenous | 1 | 6 hours |
| DOXOrubicin | 50 mg/m² | intravenous | 1 | 15 minutes |
| vinCRISTine | 1.4 mg/m² Cap dose per administration at: 2 mg | intravenous | 1 | 10 minutes |
| CYCLOPHOSPHamide | 750 mg/m² | intravenous | 1 | 60 minutes |
RITUximab, first dose:
- Consider withholding routine anti-hypertensives for 12 hours prior to first RITUximab dose.
- For patients at high risk of infusion-related reaction, consider additional pre-medications such as an extra antihistamine dose the day before, an H2 receptor antagonist and montelukast.
Full details
Cycles 1 to 8 - 21 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| prEDNISone | 100 mg flat dosing Once daily | oral administration |
Instructions:
Take in the morning with food, at least ONE hour prior to RITUximab. |
|
| paracetamol * | 1000 mg flat dosing | oral administration |
Instructions:
30 to 60 minutes prior to RITUximab. |
|
| loratadine * | 10 mg | oral administration |
Instructions:
30 to 60 minutes prior to RITUximab. |
|
| RITUximab | 375 mg/m² | intravenous | 6 hours |
Instructions:
First administration:
Further administrations:
|
| DOXOrubicin | 50 mg/m² | intravenous | 15 minutes |
Instructions:
Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration. |
| vinCRISTine | 1.4 mg/m² Cap dose per administration at: 2 mg | intravenous | 10 minutes |
Instructions:
|
| CYCLOPHOSPHamide | 750 mg/m² | intravenous | 60 minutes |
Day: 2
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| prEDNISone | 100 mg flat dosing Once daily | oral administration |
Instructions:
Take in the morning with food. |
Day: 3
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| prEDNISone | 100 mg flat dosing Once daily | oral administration |
Instructions:
Take in the morning with food. |
Day: 4
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| prEDNISone | 100 mg flat dosing Once daily | oral administration |
Instructions:
Take in the morning with food. |
Day: 5
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| prEDNISone | 100 mg flat dosing Once daily | oral administration |
Instructions:
Take in the morning with food. |
Supportive Care Factors
| Factor | Value |
|---|---|
| Antiviral prophylaxis for hepatitis B virus: | Required for anti–HBc positive patients at risk of reactivation |
| Antiviral prophylaxis for herpes virus: | Routine antiviral prophylaxis may be considered |
| Constipation risk: | laxatives are usually prescribed |
| Emetogenicity: | Medium |
| Gastroprotection: | Gastroprotection may be considered |
| Growth factor support: | Variable |
| Hypersensitivity / Infusion related reaction risk: | High - routine premedication recommended |
| Tumour lysis syndrome prophylaxis: | Tumour lysis syndrome prophylaxis is recommended |
Growth factor support: Consider primary prophylaxis for patients over 64 years of age or other high-risk patients.
Tumour lysis syndrome prophylaxis: Recommended for cycle 1 and consider for subsequent cycles.
References
Medicines and Hepatitis B Reactivation Prescriber Update 38(1): 2-3 March 2017 https://medsafe.govt.nz/profs/PUArticles/March2017/MedicinesAndHepatitisB.htm
Rituximab and Hepatitis B Reactivation Prescriber Update 34(3):27 September 2013 https://www.medsafe.govt.nz/profs/PUArticles/Sept2013RituximabHepB.htm
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.